| Wednesday
| Friday | Saturday
| Sunday |
| THURSDAY, DECEMBER
11, 2008 |
| 8:30-8:45 |
WELCOME – Exhibit Hall
D |
|
| |
Opening Remarks
C. Kent Osborne, MD
Charles A. Coltman, Jr., MD
|
|
| |
|
|
| 8:45-9:15 |
PLENARY LECTURE 1 – Exhibit Hall
D |
|
| |
|
|
| |
Endocrine therapy combined with signal transduction inhibitors – a
means to overcome resistance?
Stephen Johnston, MA, PhD, FRCP
Royal Marsden NHS Foundation Trust and Institute of Cancer Research
London, UNITED KINGDOM
|
|
| |
|
|
| 9:15-11:30 |
GENERAL SESSION 1–
Exhibit Hall D |
|
| |
Jim Ingle, MD, Co-Moderator
Mayo Clinic, Rochester, MN
and
Hyman Muss, MD, Co-Moderator
Vermont Cancer Center, Burlington, VT
|
|
| |
|
|
| 9:15 |
11. Effects of 5 years of treatment with lasofoxifene on incidence of
breast cancer in older women.
|
|
| |
LaCroix AZ, Cummings SR, Delmas P, Eastell R, Ensrud K, Reid DM, Vukicevic
S, Armstrong RA, Thompson J,Thompson D, Wolter K, Allred C, Goss P,
Osborne CK, Powles TJ. Fred Hutchinson Cancer Research Center, Seattle,
WA; CPMC Research Institute, San Francisco, CA; U. of Lyon, Lyon, France;
Sheffield U., Sheffield, United Kingdom; U. of Minnesota, Minneapolis,
MN; U. of Aberdeen Medical School, Aberdeen, United Kingdom; Zagreb
Medical School, Zagreb, Croatia; Pfizer Inc., New London, CT; Washington
U. School of Medicine, St. Louis, MO; Harvard Medical School, Boston,
MA; Baylor College of Medicine, Houston, TX ; Parkside Oncology Centre,
London, United Kingdom. |
|
| |
|
|
| 9:30 |
12. Aromatase inhibitors versus tamoxifen as adjuvant therapy
for postmenopausal women with estrogen receptor positive breast
cancer: meta-analyses of randomized trials of monotherapy and
switching strategies
|
|
| |
Ingle JN, Dowsett M, Cuzick J, Davies C. Mayo Clinic, Rochester, MN;
Royal Marsden Hospital, London, United Kingdom; Wolfson Institute,
London, United Kingdom; Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG), Oxford, United Kingdom. |
|
| |
|
|
| 9:45 |
13. BIG 1-98: a randomized double-blind phase III study evaluating
letrozole and tamoxifen given in sequence as adjuvant endocrine
therapy for postmenopausal women with receptor-positive breast
cancer
|
|
| |
Mouridsen HT, Giobbie-Hurder A, Mauriac L, Paridaens R, Colleoni M,
Thuerlimann B, Forbes JF, Gelber RD, Wardley A, Goldhirsch A. BIG 1-98
Collaborative Group and International Breast Cancer Study Group (IBCSG),
Bern, Switzerland. |
|
| |
|
|
| 10:00 |
14. Tamoxifen and anastrozole as a sequencing strategy in
postmenopausal women with hormone-responsive early breast
cancer: updated data from the Austrian breast and colorectal cancer
study group trial 8
|
|
| |
Jakesz R, Gnant M, Griel R, Tausch C, Samonigg H, Kwasny W, Kubista E,
Stierer M, Luschin G, Mittlböck M. Vienna Medical School, Vienna, Austria;
Paracelsus Medical School, Salzburg, Austria; BHS Hospital, Linz, Austria;
Graz Medical School, Graz, Austria; Wiener Neustadt Hospital, Wiener
Neustadt, Austria; Hanusch Medical Center, Vienna, Austria. |
|
| |
|
|
| 10:15 |
15. Results of the first planned analysis of the TEAM (tamoxifen
exemestane adjuvant multinational) prospective randomized phase
III trial in hormone sensitive postmenopausal early breast cancer
|
|
| |
Jones SE, Seynaeve C, Hasenburg A, Rae D, Vannetzel J-M, Paridaens
R, Markopoulos C, Hozumi Y, Putter H, Hille E, Kieback D, Asmar L,
Smeets J, Urbanski R, Bartlett JMS, van de Velde CJH. US Oncology
Research, Inc., Houston, TX; Erasmus MC Daniel Den Hoed, Rotterdam,
Netherlands; University Hospital Freiburg, Freiburg, Germany; The
University of Birmingham, Birmingham, United Kingdom; Institut du Sein
Henri Hartmann (ISHH), Neuilly sur Seine, France; U. Z. Gasthuisberg,
Leuven, Belgium; Athens University Medical School, Athens, Greece; Jichi
Medical University, Shimotsuke, Japan; Leiden University Medical Center,
Leiden, Netherlands; Helios Medical Center, Aue, Germany; Pfizer, New
York; Endocrine Cancer Group, Edinburgh University, Edinburgh, United
Kingdom.
|
|
| |
|
|
| 10:30 |
16. A randomized phase 2 trial of low dose (6 mg daily) versus high
dose (30 mg daily) estradiol for patients with estrogen receptor
positive aromatase inhibitor resistant advanced breast cancer |
|
| |
Ellis MJ, Dehdahti F, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Jeffe
DB, Gao F, Fleming G, Silverman P, Dickler M, Carey L, Marcom PK. Siteman
Cancer Center, St Louis, MO; University of Chicago, Chicago, IL; Case
Western Reserve University, Cleveland, OH; MSKCC, New York, NY; UNC,
Chapel Hill, NC; Duke University, Durham, NC. |
|
| |
|
|
| 10:45 |
17. Preclinical modeling of endocrine response: a combination
therapy approach with the ERß agonist, diarryl propionitrile and
letrozole restores sensitivity to letrozole-resistant breast cancer cells |
|
| |
Nair HN, Jayarajan R, Saha SR, Veerapaneni P, Santhamma B, Kirma NB, Perla
RP, Joseph AK, Evans DB, Brodie AH, Tekmal RR. University of Texas Health
Science Center at San Antonio, San Antonio, TX; Novartis Institutes for
Biomedical Research, Basel, Switzerland; University of Maryland, Baltimore,
MD. |
|
| |
|
|
| 11:00 |
18. ER-α36, a variant of ER-α, is the estrogen receptor that mediates
mitogenic estrogen signaling in breast cancer cells |
|
| |
Ding L, Zhang X, Wang Z. 2nd affiliated hospital, Zhejiang University,
Hangzhou, Zhejiang, China; Creighton University Medical School, Omaha,
NE. |
|
| |
|
|
| 11:15 |
19. Endoxifen, but not 4-hydroxytamoxifen, degrades the estrogen
receptor in breast cancer cells: a differential mechanism of action
potentially explaining CYP2D6 effect |
|
| |
Hawse JR, Wu X, Subramaniam M, Goetz MP, Spelsberg TC, Ingle JN. Mayo
Clinic, Rochester, MN. |
|
| |
|
|
| 11:30-12:00 |
AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH, supported by an educational grant from Susan G. Komen for the Cure - Exhibit Hall D |
|
| |
Recent developments in genetic susceptibility to breast cancer
|
|
| |
Douglas Easton, PhD, FMedSci
University of Cambridge
Cambridge, UNITED KINGDOM |
|
| |
|
|
| 12:00-1:15 |
LUNCH [Ticket Required] – Exhibit
Hall A |
|
| |
|
|
| 12:30-1:15 |
CAREER SURVIVAL FORUM: A Networking Session for Young
Investigators – Ballroom A |
|
| |
Early-career scientists -- graduate and medical students, residents, and
postdoctoral and clinical fellows -- are invited to attend this new lunchtime
event designed to provide insight into the survival skills needed to establish
a successful cancer research career. Don’t miss this opportunity to get
valuable advice and mentorship from senior scientists, who will lead
discussion at roundtables on a variety of topics such as grantsmanship,
paper publishing, and oral presentations. Attendees can also build their
network of established investigators and peers in the field of breast cancer
research.
Space is limited, and pre-registration is required. Return the registration form by November 24, 2008.
Lunch is not provided, however attendees are welcome to purchase their
lunch and bring it with them to the session room. The list of mentors and
topics may also be viewed on the website.
This session is organized by the AACR Women in Cancer Research,
Minorities in Cancer Research, and Associate Member Councils. |
|
| |
|
|
| 1:30-3:00 |
MINI-SYMPOSIUM 1– Exhibit Hall D |
|
| |
Risk Assessment and Risk Reduction Strategies
J. Dirk Iglehart, MD, Co-Moderator
Dana-Farber Cancer Institute, Boston, MA
and
Lynn C. Hartmann, MD, Co-Moderator
Mayo Clinic, Rochester, MN |
|
| |
|
|
| 1:30 |
Introduction |
|
| |
|
|
| 1:40 |
Risk assessment and risk reduction strategies: Overview |
|
| |
Lynn C. Hartmann, MD
Mayo Clinic
Rochester, MN |
|
| |
|
|
| 2:00 |
Management of the contralateral breast in women with breast cancer |
|
| |
Todd M. Tuttle, MD, MPH
University of Minnesota
Minneapolis, MN |
|
| |
|
|
| 2:20 |
Diagnosis and prevention of breast cancer in women at high risk |
|
| |
William C. Wood, MD
Emory University School of Medicine
Atlanta, GA |
|
| |
|
|
| 2:40 |
Communicating with patients and the risk of cancer risk
predictions |
|
| |
Joann G. Elmore, MD, MPH
University of Washington
Seattle, WA |
|
| |
|
|
| 3:00-4:15 |
GENERAL SESSION 2–
Exhibit Hall D |
|
| |
George Sledge, MD, Co-Moderator
Indiana University Cancer Center, Indianapolis, IN
and
Rajeshwar Tekmal, PhD, Co-Moderator
UT Health Science Center San Antonio, San Antonio, TX |
|
| |
|
|
| 3:00 |
21. Quality of life in relation to hormonal treatment of
postmenopausal women in the Dutch Tamoxifen Exemestane
Adjuvant Multicentre (TEAM) trial |
|
| |
van Nes JGH, Voskuil DW, van Leeuwen FE, Junggeburt JMC, de Haes HCJM,
van de Velde CJH. LUMC, Leiden, Netherlands; NKI/AVL, Amsterdam,
Netherlands; AMC, Amsterdam, Netherlands.
|
|
| |
|
|
| 3:15 |
22. Can nipple-areola-sparing mastectomy be an alternative to
mastectomy? Over 10 years of follow up at a Japanese institution
|
|
| |
Sakurai T, Umemura T, Jinta E, Shimizu S, Suzuma T, Yoshimura G, Sakurai
T. Wakayama Medical Univ Kihoku Hospital, Ito, Wakayama, Japan; Sakurai
Breast Clinic, Wakayama, Japan; Kushimoto Arida Hospital, Kushimoto,
Wakayama, Japan; Kishiwada Shimin Hospital, Kishiwada, Osaka, Japan. |
|
| |
|
|
| 3:30 |
23. Micrometastases and isolated tumor cells: relevant and robust or
rubbish? (MIRROR): preliminary results of the MIRROR study from
the Dutch breast cancer trialists’ group (BOOG) |
|
| |
de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang
EM, Nortier HW, Rutgers EJ, Seynaeve C, Menke-Pluymers MB, Bult P,
Tjan-Heijnen VC. University Medical Centre, Maastricht, Netherlands;
Comprehensive Cancer Centre (CCC) East, Nijmegen, Netherlands;
University Medical Centre, Utrecht, Netherlands; University Medical
Centre St. Radboud, Nijmegen, Netherlands; University Medical Centre,
Leiden, Netherlands; The Netherlands Cancer Institute - AvL, Amsterdam,
Netherlands; Erasmus Medical Centre - DDH, Rotterdam, Netherlands. |
|
| |
|
|
| 3:45 |
24. Aberrent hedgehog signaling is an early event in breast cancer
development
|
|
| |
O’Toole S, Swarbrick A, Millar E, McLeod D, McNeil C, Qiu MR, Lopez-Knowles E, Caldon E, Oakes S, Ormandy C, Morey A, Musgrove E, Henshall S, Sutherland R. Garvan Institute of Medical Research, Darlinghurst,
NSW, Australia; St Vincent’s Hospital, Darlinghurst, NSW, Australia; St
George Hospital, Kogarah, NSW, Australia; Royal Prince Alfred Hospital,
Camperdown, NSW, Australia. |
|
| |
|
|
| 4:00 |
25. GRB7-dependent pathways are potential therapeutic targets in
triple-negative breast cancer |
|
| |
Sparano JA, Gray R, Goldstein LJ, Childs BH, Bugarini R, Rowley S, Baker
J, Shak S, Badve S, Baehner FL, Perez EA, Shulman LN, Martino S, Sledge
GW, Davidson NE. Eastern Cooperative Oncology Group, Brookline, MA;
Genomic Health, Inc., Redwood City, CA; sanofi-aventis, Bridgewater, NJ;
North Central Cancer Treatment Group, Rochester, MN; Cancer and
Leukemia Group B, Chicago, IL; Southwest Oncology Group, Ann Arbor, MI. |
|
| |
|
|
| 4:15-5:30 |
SUSAN G. KOMEN FOR THE CURE
BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES– Exhibit
Hall D
|
|
| |
|
|
| 4:15 |
Introduction |
|
| |
|
|
| 4:20 |
Molecular insights into breast cancer metastasis
Patricia Steeg, PhD
National Cancer Institute
Bethesda, MD |
|
| |
|
|
| 4:50 |
Tailoring Adjuvant Treatments for the Individual Patient with Breast Cancer (Part 1)
Richard Gelber, PhD
Dana Farber Cancer Institute
Boston, MA
|
|
| |
|
|
| 5:10 |
Tailoring Adjuvant Treatments for the Individual Patient with Breast Cancer (Part 2)
Aron Goldhirsch, MD
European Institute of Oncology
Milan, ITALY |
|
| |
|
|
| 5:30-7:30 |
POSTER DISCUSSION 1 & RECEPTION – Ballroom A
|
|
| |
Microenvironment & Stem Cells |
101-108 |
| |
|
|
| 5:30-7:30 |
POSTER DISCUSSION 2 & RECEPTION – Ballroom B
|
|
| |
Sentinel Nodes |
201-207 |
| |
|
|
| 5:30-7:30 |
POSTER SESSION
1 & RECEPTION – Exhibit Hall B
|
|
| |
(#1001-1165) |
|
| |
|
|
| |
Detection/ Diagnosis
Axillary Staging and Sentinel Nodes |
1001-1026
|
| |
|
|
| |
Tumor Cell and Molecular Biology
Angiogenesis
DNA Damage and Repair
Genetics/Germline Changes
Tumor Microenvironment
Tumor Heterogeneity/ Molecular Subclassification
|
1027-1037
1038-1039
1040-1047
1048-1057
1058-1060 |
| |
|
|
| |
Prognosis and Response Prediction
Prognostic Factors and Biomarkers -
Clinical Testing and Validation
|
1061-1092
|
| |
|
|
| |
Risk, Epidemiology and Prevention
Familial Breast Cancer - Genetic Testing
Familial Breast Cancer - Molecular Genetics
Prevention - Preclinical Studies and Model Systems |
1093-1104
1105-1106
1107-1113 |
| |
|
|
| |
Social, Behavioral, Economic and Outreach Studies
Survivorship Research
|
1114-1126
|
| |
|
|
| |
Treatment
Adjuvant Endocrine Therapy
Bone Metasteses
DCIS/LCIS |
1127-1154
1155-1160
1161-1165 |
| |
|
|
| 7:30-10:00 |
SUSAN G. KOMEN
FOR THE CURE BRINKER AWARDS FOR SCIENTIFIC DISTINCTION DINNER
Grand Hyatt - Texas Ballroom |
|
| |
Susan G. Komen for the Cure proudly presents the 2008 Brinker Awards for Scientific Distinction Reception and Dinner
7:30 pm Reception
8:00 pm Dinner and Award Presentation
Please purchase your tickets to the 2008 Brinker Dinner when registering at www.sabcs.org. You may also purchase your tickets onsite at the Susan G. Komen for the Cure booth. Tickets will be sold on a first-come, first-served basis.
If you have additional questions, please contact sdeland@komen.org. We look forward to seeing you in San Antonio! |
|
|
Home
Registration
Schedule at a Glance
